retatrutide and liver Triple hormone receptor agonist for metabolic dysfunction-associated steatotic disease: a randomized phase 2a trial Retatrutide Benefits: 24% Weight Loss

It is not known whether either of these routes is currently available for retatrutide

Research from the National Institutes of Health shows that fluid losses as small as two percent of body weight can reduce concentration, increase fatigue, and impair physical performance

Ussher, J.R

The lean mass loss data is certainly a critical point for clinicians to consider when weighing the risk-benefit ratio of retatrutide, especially given the potential for long-term sarcopenia

Another promising direction involves dissolving microneedles, which completely degrade upon administration, eliminating the need for disposal and improving patient compliance